JPS50105624A - - Google Patents

Info

Publication number
JPS50105624A
JPS50105624A JP49124718A JP12471874A JPS50105624A JP S50105624 A JPS50105624 A JP S50105624A JP 49124718 A JP49124718 A JP 49124718A JP 12471874 A JP12471874 A JP 12471874A JP S50105624 A JPS50105624 A JP S50105624A
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP49124718A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPS50105624A publication Critical patent/JPS50105624A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/29—Polyamino acid or polypeptide with an uninterrupted series of peptide repeating units

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP49124718A 1973-11-02 1974-10-29 Pending JPS50105624A (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US412419A US3891696A (en) 1973-11-02 1973-11-02 Novel, transient pro-drug forms of l-dopa

Publications (1)

Publication Number Publication Date
JPS50105624A true JPS50105624A (OSRAM) 1975-08-20

Family

ID=23632886

Family Applications (3)

Application Number Title Priority Date Filing Date
JP49124717A Expired JPS5756907B2 (OSRAM) 1973-11-02 1974-10-29
JP49124718A Pending JPS50105624A (OSRAM) 1973-11-02 1974-10-29
JP49126692A Pending JPS5088043A (OSRAM) 1973-11-02 1974-11-02

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP49124717A Expired JPS5756907B2 (OSRAM) 1973-11-02 1974-10-29

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP49126692A Pending JPS5088043A (OSRAM) 1973-11-02 1974-11-02

Country Status (2)

Country Link
US (1) US3891696A (OSRAM)
JP (3) JPS5756907B2 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998799A (en) * 1973-11-02 1976-12-21 Interx Research Corporation Novel, transient pro-drug forms of l-dopa
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
DE2510634A1 (de) * 1975-03-12 1976-09-23 Boehringer Mannheim Gmbh L-3-(3,4-dihydroxy-phenyl)-2- methyl-alanin-peptide und verfahren zu deren herstellung
US4254273A (en) * 1975-06-11 1981-03-03 Merck & Co., Inc. Process for preparing esters of α-methyl-3,4-dihydroxyphenylalanine
US4031242A (en) * 1975-09-11 1977-06-21 Abbott Laboratories Diacylated derivatives of γ-glutamyl dopamine
PH14064A (en) * 1977-05-06 1981-01-26 Pfizer Phenylgycine derivatives,pharmaceutical compositions and method of use
US4271187A (en) * 1978-06-05 1981-06-02 Merck & Co., Inc. Substituted phenyl alanine antihypertensive agents
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4311706A (en) * 1980-01-22 1982-01-19 Interx Research Corporation Novel dopa/dopamine prodrugs
JPS59112949A (ja) * 1982-12-20 1984-06-29 Microbial Chem Res Found 新規なｌ−スレオ−アドレナリン酸
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) * 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
JP2554271B2 (ja) * 1988-08-12 1996-11-13 日本化薬株式会社 （−）−Ｎ−（１−アルコキシカルボニルプロペン−２−イル）−ａ−アミノ−ａ−（ｐ−ヒドロキシフエニル）酢酸アルカリ金属塩の製造法
ATE118216T1 (de) * 1989-04-20 1995-02-15 Zambon Spa Dopamin-medikament-vorstufe.
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
EP1670433B1 (en) 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
DE102005022276A1 (de) * 2005-05-13 2006-11-16 Ellneuroxx Ltd. Derivate von Dihydroxyphenylalanin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US8377474B2 (en) 2007-12-28 2013-02-19 Impax Laboratories, Inc. Controlled release formulations of levodopa and uses thereof
AU2009236078B2 (en) * 2008-04-18 2014-03-06 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating age-related macular degeneration
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN103694127B (zh) * 2013-12-30 2015-04-01 上海交通大学 链霉菌属菌种所产的化合物及该化合物的制备方法和应用
EP3075723B1 (en) 2015-03-30 2017-05-24 Berlirem GmbH Highly soluble l-dopa glycerol esters
EP3277660B1 (en) 2015-03-30 2019-10-16 Berlirem GmbH Water-soluble l-dopa esters
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
AU2019379806B2 (en) 2018-11-15 2025-08-14 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
EP3917504A1 (en) 2019-01-31 2021-12-08 Arizona Board of Regents on behalf of the University of Arizona Compositions and methods for treating or limiting development of age-related macular degeneration
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475193A (de) * 1966-06-07 1969-07-15 Hoffmann La Roche Verfahren zur Herstellung von Phenylalaninderivaten
CH483397A (de) * 1966-12-01 1969-12-31 Hoffmann La Roche Verfahren zur Herstellung von Phenylalaninderivaten
US3734952A (en) * 1968-12-27 1973-05-22 Hoffmann La Roche Preparation of l-dopa
US3676482A (en) * 1969-03-14 1972-07-11 Merck & Co Inc Racemization of an alpha-methyl dopa derivative
US3714241A (en) * 1969-10-29 1973-01-30 Merck & Co Inc PREPARATION OF alpha -METHYL-3,4-DISUBSTITUTED PHENYLALANINES
DE1963991C3 (de) * 1969-12-20 1975-05-15 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Gewinnung eines Derivates von L-3,4-dihydroxyphenylalanin
US3715382A (en) * 1970-02-05 1973-02-06 Merck & Co Inc N-ACYL- alpha -HYDRAZINO- beta -(PHENYL) PROPIONITRILES
US3717673A (en) * 1970-04-04 1973-02-20 L Bernardi Process for the preparation of l-dopa
JPS528820B1 (OSRAM) * 1970-05-04 1977-03-11
US3714242A (en) * 1970-07-06 1973-01-30 Hoffmann La Roche Process for the preparation of l-dopa
DE2039253A1 (de) * 1970-08-07 1972-02-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von L-DOPA
JPS5025465B1 (OSRAM) * 1970-12-29 1975-08-23
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine

Also Published As

Publication number Publication date
JPS5756907B2 (OSRAM) 1982-12-02
US3891696A (en) 1975-06-24
JPS5088043A (OSRAM) 1975-07-15
JPS50105623A (OSRAM) 1975-08-20

Similar Documents

Publication Publication Date Title
AU476761B2 (OSRAM)
AU474593B2 (OSRAM)
AU474511B2 (OSRAM)
JPS5756907B2 (OSRAM)
AU474838B2 (OSRAM)
AU465453B2 (OSRAM)
AU471343B2 (OSRAM)
AU465434B2 (OSRAM)
AU476714B2 (OSRAM)
AU472848B2 (OSRAM)
AU466283B2 (OSRAM)
AU476696B2 (OSRAM)
AU477823B2 (OSRAM)
AU471461B2 (OSRAM)
AR193950A1 (OSRAM)
AU477824B2 (OSRAM)
AU476873B1 (OSRAM)
CH560912A5 (OSRAM)
BG18936A1 (OSRAM)
AU479522A (OSRAM)
AU479521A (OSRAM)
AU479504A (OSRAM)
AU479496A (OSRAM)
AU479458A (OSRAM)
AU479453A (OSRAM)